Analysts lift target to NZD 3.07 for Ryman Healthcare stock

Published on 10/15/2026 at 19:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 25, 2026. Ryman Healthcare stock costs EUR 0.87 on October 15, 2026 at 7:49 p.m. CEST, up 1.70 percent on the NZX.

Analyst target update

Analysts raised the average target from NZD 2.83 to NZD 3.07 on October 15, 2026.
Ryman Healthcare will report six-month results on November 25, 2026.
Ryman Healthcare stock costs EUR 0.87 at 7:49 p.m. CEST at Lang & Schwarz on October 15, 2026, up 1.70 percent on the NZX versus the previous close.
Market capitalization stood at NZD 1.8 billion on October 15, 2026.

RYM, NZRYME0001S4, Illustration mit AI erstellt.

Ryman Healthcare stock (ISIN NZRYME0001S4) gained a higher valuation marker on October 15, 2026, when the average analyst target rose from NZD 2.83 to NZD 3.07. The new target is 71.51 percent above the NZD 1.79 home-exchange price, based on the same-day quotation. Simply Wall St reported the target change and said the average covered four analysts. At Lang & Schwarz, the stock was trading at EUR 0.87 on October 15, 2026 at 7:49 p.m. CEST, while the NZX session was up 1.70 percent versus its previous close.

November 25 results date

Ryman Healthcare will report results for the six months to September 30, 2026, on November 25, 2026. The date was published by BusinessDesk on October 15, 2026, which also listed an 11:00 a.m. New Zealand time investor webcast. That event gives the next scheduled checkpoint for revenue, occupancy and cash generation.

Price position and operating scale

Ryman Healthcare's fiscal year 2026 revenue was NZD 855.6 million, up 13.00 percent from fiscal year 2025, while the net loss narrowed to NZD 171.3 million from NZD 436.8 million. The figures were reported by Simply Wall St for the year ended March 31, 2026. Ryman's NZX price of NZD 1.79 was 41.31 percent below the NZD 3.05 fiscal-year offering price cited in the same report.

Valuation and business scale

The home-market quotation carried a market capitalization of NZD 1.8 billion on October 15, 2026. Its price-to-earnings ratio was minus 10.88, reflecting the reported loss, while the trailing dividend yield was 0.00 percent. Ryman's investor page says the company operates retirement villages and aged-care facilities across New Zealand and Australia, with more than 15,500 residents and about 7,800 employees. The company is dual listed on the NZX and ASX.

Comparison with peers

RYM (NZX, NZD): plus 1.70 percent, price-to-earnings ratio minus 10.88, market capitalization NZD 1.8 billion.
Summerset Group Holdings (NZX, NZD): minus 0.44 percent, price-to-earnings ratio 5.40, market capitalization NZD 1.7 billion.
Mainfreight (NZX, NZD): plus 2.90 percent, price-to-earnings ratio 26.96, market capitalization NZD 6.8 billion.

Trading perspective

The target revision and the November reporting date give investors two separate markers for assessing whether Ryman's restructuring is translating into improved earnings. The market capitalization is close to the company's NZD 1.8 billion fiscal-year revenue, while the negative earnings multiple reflects the current loss position. At Lang & Schwarz, Ryman Healthcare stock was trading at EUR 0.87 on October 15, 2026 at 7:49 p.m. CEST, with the NZX price up 1.70 percent versus its previous close. The further course of trading is shown by the continuously updated real-time quote of Ryman Healthcare stock.